ABL1 and leukemia: Ponatinib is an orally active tyrosine kinase inhibitor that was originally designed to conquer the resistance mutations of BCR-ABL leukemia (O'Hare et al., 2009), but subsequent studies have shown that it has at least 30 high affinity targets (IC50 < 10 nm) (O'Hare et al., 2009).